AMSL Diabetes partner with MannKind Corporation
Posted May 17, 2019.
Sydney, Australia, May 2019 –
AMSL Diabetes are excited to announce that they have signed a distribution agreement with MannKind Corporation (NASDAQ: MNKD) to introduce their patient-focused therapies to the Australian market. The exclusive partnership is set to benefit Australian diabetes patients by offering a new innovative technology solution to their diabetes management.
"We are excited to partner with AMSL Diabetes to bring our product to Australia" said Michael Castagna, Chief Executive Officer of MannKind Corporation. "Our founder, Alfred Mann, had a vision to bring our product to a worldwide market and with AMSL’s presence and knowledge of the diabetes market in Australia, we believe we will reach healthcare providers and patients with the message that our product is an incredible option in the fight against diabetes."
MannKind Corporation will retain responsibility for product development, quality management and manufacturing while AMSL Diabetes will be responsible for regulatory and reimbursement approval, sales, marketing and customer support and distribution activities within Australia.
About MannKind Corporation
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialisation of inhaled therapeutic products for patients with medical conditions such as diabetes and pulmonary arterial hypertension. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing and research facility in Danbury, Connecticut.
For more information about this announcement, please contact AMSL Diabetes on 1300 851 056 or email diabetes@amsl.com.au.